SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sessa, B.
Right arrow Articles by Nutt, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sessa, B.
Right arrow Articles by Nutt, D. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Editorial

MDMA, politics and medical research: Have we thrown the baby out with the bathwater?

Ben Sessa

Psychopharmacology Unit, University of Bristol, Bristol, UK

David J. Nutt

Psychopharmacology Unit, University of Bristol, Bristol, UK, david.j.nutt{at}bristol.uk

References

  • Bell C.J., Hood S.D., Nutt D.J. (2005) Acute tryptophan depletion. Part II: clinical effects and implications. ANZ J Psychiatry 39(7): 565—574
  • Bonnie, Whitebread C H (1999) The Marijuana Conviction: A History of Marijuana Prohibition in the United States. New York: Drug Policy Alliance. July 1999, 368—370
  • Cami J., Farre M., Mas M., Roset P.N., Poudevida S., Mas A., San L., de la Torre R. (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine (`ecstasy'): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455—466[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Greer G.R., Tolbert R. (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18(4): 319—327[Web of Science][Medline] [Order article via Infotrieve]
  • Grinspoon L., Bakalar J.B. (1995) Marihuana as medicine: a plea for reconsideration. JAMA 273(23): 1875—1876[Abstract/Free Full Text]
  • Grob C. ( 2002) Appendix B., Deconstructing Ecstasy: The Politics of MDMA research. From `Hallucinogens — A Reader'. Published by Tarcher/Putnam.
  • Halpern J.H., Pope H.G., Sherwood A.R., Barry S., Hudson J.I., Yurgelun-Todd D. (2004) Residual neuropsychological effects of illicit MDMA in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135—147[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hood S.D., Bell C.J., Nutt D.J. (2005) Acute tryptophan depletion. Part I: rationale and methodology. ANZ J Psychiatry 39(7): 558—564
  • Huizink A.C., Ferdinand R.F., van der Ende J., Verhulst F.C. (2006) Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. BMJ 332: 825—828[Abstract/Free Full Text]
  • Iverson L. (2006) Speed, ecstasy, ritalin: the science of amphetamines. Chapter 8, Ecstasy. Pages 151—152. Oxford University Press, Oxford
  • Johnson M.P., Hoffma A.J., Nichols D.E. (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132: 269—296[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lee M.A., Shalin B. (1992) Acid dreams. The complete social history of LSD: the CIA, the sixties and beyond. Chapter 3, Pages 87—95. Grove Press, New York
  • Lieb R., Schuetz C., Pfister H., von Sydow K., Wittchen H. (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68(2): 195[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Liechti M.E. (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154:161—168[CrossRef][Medline] [Order article via Infotrieve]
  • Liester M.B., Grob C.S., Bravo G.L., Walsh R.N. (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nervous Mental Dis 180: 345—352[Web of Science][Medline] [Order article via Infotrieve]
  • Ludewig S., Ludewig K., Hasler F., Vollenweides F.X. (2003) No lasting effects of moderate doses of MDMA on memory performance and mood states in healthy humans. Biol Psychiatry 53 (Suppl): 2055
  • Molliver M.E., Berger U.V., Mamounas L.A., Molliver D.C., O'Hearn E., Wislon M.A. (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 600: 640—664[CrossRef][Web of Science]
  • National Criminal Intelligence Service (2001 ) UK Threat Assessment 2001, produced by the National Criminal Intelligence Service
  • Nutt D.J., King L.A., Saulsbury W., Blakemore C. (2007) The development of a rational scale to assess the harm of drugs of potential misuse. The Lancet 369: 1047—1053
  • Office of National Statistics (2002) — Deaths related to drug poisoning in England and Wales 1993—2000 and 1998—2002. Health Statistic Quarterly, Spring 2003 and Spring 2004
  • Office of National Statistics (2002 and 2003) Mortality Statistics — Review of the Register General on Death in England and Wales, 2002 and 2003
  • Parrott A.C. (2007) The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology 191: 181—193[CrossRef][Medline] [Order article via Infotrieve]
  • Reneman L., Endert E., de Bruin K., Lavalaye J., Feenstra M.G., de Wolff F.A., Booij J.L. (2002) The acute and chronic effects of MDMA (`Ecstasy') on cortical 5-HT2A receptors in rat and human brain Neuropsychopharmacology 26: 387396.10.1038/S0893-133X(01)00366-9
  • Ricaurte G., Bryan G., Strauss L., Seiden L., Schuster C. (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986—988[Abstract/Free Full Text]
  • Riedlinger J., Montagne M. (2001) Potential clinical uses for MDMA. In Holland J (Ed.). Ecstasy: the complete guide: a comprehensive review of the risks and benefits of MDMA. Inner Traditions 261—272
  • Sessa B. (2007) Is there a case for MDMA-assisted psychotherapy in the UK? J Psychopharmacol 21: 220—221[Abstract/Free Full Text]
  • Shulgin A.T. (1986) The background and chemistry of MDMA. J Psychoactive Drugs 18: 291—304[Web of Science][Medline] [Order article via Infotrieve]
  • Steele D.M., Nichols D.E., Yim G K W (1987) Sterochemical effects of 3,4-methylenedioxymethlyamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) and related amphetamine derivatives on inhibition of uptake of [3H]-monoamines into synaptosomes for different regions of rat brain. Biochem Pharmacol 36: 2297—2303[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sumnall H.R., Cole J.C., Jerome L. (2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol 2006, Published: On-line
  • UK Home Office (1971) Misuse of drugs act. www.drugs.gov.uk
  • Vollenweider F.X., Gamma A., Liechti M., Huber T. (1998a) Psychological and cardiovascular effects and short-term sequlae of MDMA (`ecstasy') in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19: 241—251[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Psychopharmacology, Vol. 21, No. 8, 787-791 (2007)
DOI: 10.1177/0269881107084738


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
A. Green, C. Marsden, and K. Fone
MDMA as a clinical tool: a note of caution. A response to Sessa and Nutt
J Psychopharmacol, November 1, 2008; 22(8): 929 - 931.
[PDF]


Home page
J PsychopharmacolHome page
B Sessa and D Nutt
Reply to letter by Green, Marsden and Fone (2007) about Sessa and Nutt's editorial (MDMA: baby with the bath water) in the November 2007 Journal
J Psychopharmacol, June 1, 2008; 22(4): 457 - 458.
[PDF]


This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sessa, B.
Right arrow Articles by Nutt, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sessa, B.
Right arrow Articles by Nutt, D. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement